ChromaDex Corp (NAS:CDXC)
$ 2.79 -0.14 (-4.78%) Market Cap: 210.75 Mil Enterprise Value: 197.14 Mil PE Ratio: 0 PB Ratio: 7.15 GF Score: 78/100

Q3 2019 Chromadex Corp Earnings Call Transcript

Nov 12, 2019 / 09:30PM GMT
Release Date Price: $2.83 (-0.70%)
Operator

Thank you for standing by and welcome to the ChromaDex Third Quarter 2019 Earnings Conference Call. (Operator Instructions)

Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Brianna Gerber, Vice President of FP&A and Investor Relations. Please go ahead.

Brianna Gerber
ChromaDex Corporation - Senior Director of FP&A and IR

Thank you. Good afternoon, and welcome to ChromaDex Corporation's Third Quarter 2019 Results Investor Call. With us today are ChromaDex's Chief Executive Officer, Rob Fried; Founder and Executive Chairman, Frank Jaksch; and Chief Financial Officer, Kevin Farr.

Today's conference may include forward-looking statements, including statements related to ChromaDex's research and development and clinical trial plans and the timing and results of such trials, the timing of future regulatory filings, the expansion of the sale of TRU NIAGEN in new markets, future financial results, business development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot